-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Earlier, Genmab To Submit sBLA To FDA for Epcoritamab Plus R2 In Relapsed/Refractory Follicular Lymphoma Following Positive Phase 3 Data

Benzinga·05/02/2025 06:01:45
Listen to the news
  • Decision to submit based on a positive overall response rate (ORR) (p-value < 0.0001), one of the dual primary endpoints in the Phase 3 EPCORE® FL-1 trial
  • Full results from the trial will be submitted for presentation at an upcoming medical conference in 2025